Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife
PurposeHemangiopericytomas are aggressive tumors known for their recurrence. The purpose of this study was to evaluate the management of residual, recurrent, and metastatic intracranial hemangiopericytomas using CyberKnife (CK) stereotactic radiotherapy (SRT).Materials and MethodsData were collected...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.577054/full |
| _version_ | 1818353388432130048 |
|---|---|
| author | Lichao Huang Lichao Huang Jingmin Bai Yanyang Zhang Zhiqiang Cui Zhizhong Zhang Jiwei Li Jinyuan Wang Xinguang Yu Zhipei Ling Baolin Qu Longsheng Pan |
| author_facet | Lichao Huang Lichao Huang Jingmin Bai Yanyang Zhang Zhiqiang Cui Zhizhong Zhang Jiwei Li Jinyuan Wang Xinguang Yu Zhipei Ling Baolin Qu Longsheng Pan |
| author_sort | Lichao Huang |
| collection | DOAJ |
| description | PurposeHemangiopericytomas are aggressive tumors known for their recurrence. The purpose of this study was to evaluate the management of residual, recurrent, and metastatic intracranial hemangiopericytomas using CyberKnife (CK) stereotactic radiotherapy (SRT).Materials and MethodsData were collected from 15 patients (28 tumors; eight men and seven women; 32–58 years) with residual, recurrent, or metastatic intracranial hemangiopericytomas, who were treated with stereotactic radiotherapy using CyberKnife between January 2014 and August 2019. All patients had previously been treated with surgical resection. Initial tumor volumes ranged from 0.84 to 67.2 cm3, with a mean volume of 13.06 cm3. The mean marginal and maximum radiosurgical doses to the tumors were 21.1 and 28.76 Gy, respectively. The mean follow-up time for tumors was 34.5 months, ranging from 13 to 77 months.Results15 patients were alive after treatment; the mean post-diagnosis survival at censoring was 45.6 months (range 13–77 months). The volumes of the 28 tumors in the 15 followed patients were calculated after treatment. Postoperative magnetic resonance imaging revealed a mean tumor volume of 6.72 cm3 and a range of 0–67.2 cm3, with the volumes being significantly lower than pretreatment values. Follow-up imaging studies demonstrated tumor disappearance in seven (25%) of 28 tumors, reduction in 14 (50%), stability in one (3.57%), and recurrence in six (21.4%). Total tumor control was achieved in 22 (78.5%) of 28 tumors. The tumor grade and fraction time were not significantly associated with progression-free survival. Intracranial metastasis occurred in three patients, and extraneural metastasis in one patient.ConclusionsOn the basis of the current results, stereotactic radiotherapy using CyberKnife is an effective and safe option for residual, recurrent, and metastatic intracranial hemangiopericytomas. Long-term close clinical and imaging follow-up is also necessary. |
| first_indexed | 2024-12-13T19:08:44Z |
| format | Article |
| id | doaj.art-42df450ce2484e54a8f4e3443553339e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T19:08:44Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-42df450ce2484e54a8f4e3443553339e2022-12-21T23:34:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.577054577054Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnifeLichao Huang0Lichao Huang1Jingmin Bai2Yanyang Zhang3Zhiqiang Cui4Zhizhong Zhang5Jiwei Li6Jinyuan Wang7Xinguang Yu8Zhipei Ling9Baolin Qu10Longsheng Pan11Department of Neurosurgery, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The Hospital of 81st Group Army PLA, Zhangjiakou, ChinaDepartment of Radiation Oncology, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Radiation Oncology, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Radiation Oncology, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Radiation Oncology, The First Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Neurosurgery, The First Medical Center of PLA General Hospital, Beijing, ChinaPurposeHemangiopericytomas are aggressive tumors known for their recurrence. The purpose of this study was to evaluate the management of residual, recurrent, and metastatic intracranial hemangiopericytomas using CyberKnife (CK) stereotactic radiotherapy (SRT).Materials and MethodsData were collected from 15 patients (28 tumors; eight men and seven women; 32–58 years) with residual, recurrent, or metastatic intracranial hemangiopericytomas, who were treated with stereotactic radiotherapy using CyberKnife between January 2014 and August 2019. All patients had previously been treated with surgical resection. Initial tumor volumes ranged from 0.84 to 67.2 cm3, with a mean volume of 13.06 cm3. The mean marginal and maximum radiosurgical doses to the tumors were 21.1 and 28.76 Gy, respectively. The mean follow-up time for tumors was 34.5 months, ranging from 13 to 77 months.Results15 patients were alive after treatment; the mean post-diagnosis survival at censoring was 45.6 months (range 13–77 months). The volumes of the 28 tumors in the 15 followed patients were calculated after treatment. Postoperative magnetic resonance imaging revealed a mean tumor volume of 6.72 cm3 and a range of 0–67.2 cm3, with the volumes being significantly lower than pretreatment values. Follow-up imaging studies demonstrated tumor disappearance in seven (25%) of 28 tumors, reduction in 14 (50%), stability in one (3.57%), and recurrence in six (21.4%). Total tumor control was achieved in 22 (78.5%) of 28 tumors. The tumor grade and fraction time were not significantly associated with progression-free survival. Intracranial metastasis occurred in three patients, and extraneural metastasis in one patient.ConclusionsOn the basis of the current results, stereotactic radiotherapy using CyberKnife is an effective and safe option for residual, recurrent, and metastatic intracranial hemangiopericytomas. Long-term close clinical and imaging follow-up is also necessary.https://www.frontiersin.org/articles/10.3389/fonc.2021.577054/fullstereotactic radiotherapyCyberKnifehemangiopericytomastumor controlmanagement |
| spellingShingle | Lichao Huang Lichao Huang Jingmin Bai Yanyang Zhang Zhiqiang Cui Zhizhong Zhang Jiwei Li Jinyuan Wang Xinguang Yu Zhipei Ling Baolin Qu Longsheng Pan Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife Frontiers in Oncology stereotactic radiotherapy CyberKnife hemangiopericytomas tumor control management |
| title | Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife |
| title_full | Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife |
| title_fullStr | Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife |
| title_full_unstemmed | Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife |
| title_short | Treatment of Residual, Recurrent, or Metastatic Intracranial Hemangiopericytomas With Stereotactic Radiotherapy Using CyberKnife |
| title_sort | treatment of residual recurrent or metastatic intracranial hemangiopericytomas with stereotactic radiotherapy using cyberknife |
| topic | stereotactic radiotherapy CyberKnife hemangiopericytomas tumor control management |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.577054/full |
| work_keys_str_mv | AT lichaohuang treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT lichaohuang treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT jingminbai treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT yanyangzhang treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT zhiqiangcui treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT zhizhongzhang treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT jiweili treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT jinyuanwang treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT xinguangyu treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT zhipeiling treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT baolinqu treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife AT longshengpan treatmentofresidualrecurrentormetastaticintracranialhemangiopericytomaswithstereotacticradiotherapyusingcyberknife |